Characteristics of patients who achieved CR compared to those with primary resistance
| Patient characteristics . | Study population,n = 1179 . | Primary refractory,n = 285 . | Achieved CR,n = 894 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 57 (17-88) | 59 (18-85) | 56 (17-88) | < .001 |
| Median WBC, ×109/L (range) | 6.8 (6.3-394) | 9.0 (0.3-394) | 5.9 (0.3-390) | .04 |
| Median Plt count, ×109/L (range) | 51 (3-1355) | 45 (4-708) | 52 (3-1355) | .02 |
| Cytogenetics, n (%) | ||||
| Diploid/intermediate | 820 (70) | 183 (64) | 637 (72) | < .001 |
| Unfavorable | 235 (20) | 101 (35) | 134 (15) | |
| Favorable | 124 (10) | 1 (1) | 123 (14) | |
| FLT3 mutated, n = 584, n (%) | ||||
| Yes | 139 (24) | 32 (11) | 107 (12) | .85 |
| No | 445 (76) | 106 (37) | 339 (38) | |
| Antecedent hematological disorder, n (%) | ||||
| Yes | 473 (40) | 165 (58) | 308 (34) | |
| No | 706 (60) | 120 (42) | 586 (66) | < .001 |
| Therapy related, n (%) | ||||
| Yes | 177 (15) | 54 (19) | 123 (14) | .03 |
| No | 1002 (85) | 231 (81) | 771 (86) |
| Patient characteristics . | Study population,n = 1179 . | Primary refractory,n = 285 . | Achieved CR,n = 894 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 57 (17-88) | 59 (18-85) | 56 (17-88) | < .001 |
| Median WBC, ×109/L (range) | 6.8 (6.3-394) | 9.0 (0.3-394) | 5.9 (0.3-390) | .04 |
| Median Plt count, ×109/L (range) | 51 (3-1355) | 45 (4-708) | 52 (3-1355) | .02 |
| Cytogenetics, n (%) | ||||
| Diploid/intermediate | 820 (70) | 183 (64) | 637 (72) | < .001 |
| Unfavorable | 235 (20) | 101 (35) | 134 (15) | |
| Favorable | 124 (10) | 1 (1) | 123 (14) | |
| FLT3 mutated, n = 584, n (%) | ||||
| Yes | 139 (24) | 32 (11) | 107 (12) | .85 |
| No | 445 (76) | 106 (37) | 339 (38) | |
| Antecedent hematological disorder, n (%) | ||||
| Yes | 473 (40) | 165 (58) | 308 (34) | |
| No | 706 (60) | 120 (42) | 586 (66) | < .001 |
| Therapy related, n (%) | ||||
| Yes | 177 (15) | 54 (19) | 123 (14) | .03 |
| No | 1002 (85) | 231 (81) | 771 (86) |
CR indicates complete response; WBC, white blood cell; Plt, platelet; FLT3, FMS-like tyrosine kinase-3; unfavorable cytogenetics, 5− and/or 7−, and/or complex; and intermediate, all other abnormal cytogenetics.